English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Monday, January 16, 2023
エーザイ、抗アミロイドβプロトフィブリル抗体「レカネマブ」について、日本において早期アルツハイマー病に係る適応で新薬承認を申請
Friday, January 13, 2023
エーザイ、サステナビリティページ リニューアルのお知らせ
Eisai Launches Renewed Sustainability Page
Wednesday, January 11, 2023
Eisai Submits Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease in Europe
エーザイ、抗アミロイドβプロトフィブリル抗体「レカネマブ」について、欧州において早期アルツハイマー病に係る適応で販売承認申請を提出
Monday, January 9, 2023
Eisai Submits Supplemental Biologics License Application to FDA for Traditional Approval of LEQEMBI (lecanemab-irmb) for the Treatment of Alzheimer's Disease
FDA Approves LEQEMBI (lecanemab-irmb) Under the Accelerated Approval Pathway for the Treatment of Alzheimer's Disease
Saturday, January 7, 2023
エーザイ、LEQEMBI(TM)(レカネマブ)がアルツハイマー病に対する治療薬として米国FDAより迅速承認を取得
Thursday, January 5, 2023
エーザイ、2023年年頭所感
Wednesday, December 28, 2022
安田倉庫とエーザイ、エーザイの子会社であるエーザイ物流を安田倉庫に譲渡する契約を締結

Copyright © 2023 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575